Spots Global Cancer Trial Database for alk
Every month we try and update this database with for alk cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| ALK Rearrangements in Lung Adenocarcinoma: Epidemiology in Latin America (CLICaP) | NCT02502240 | Lung Cancer | 18 Years - 90 Years | Instituto Nacional de Cancerologia de Mexico | ||
| Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) | NCT02568267 | Breast Cancer Cholangiocarcin... Colorectal Canc... Head and Neck N... Lymphoma, Large... Melanoma Neuroendocrine ... Non-Small Cell ... Ovarian Cancer Pancreatic Canc... Papillary Thyro... Primary Brain T... Renal Cell Carc... Sarcomas Salivary Gland ... Adult Solid Tum... | Entrectinib | 18 Years - | Hoffmann-La Roche | |
| A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements | NCT03093116 | Locally Advance... Metastatic Soli... | Oral repotrecti... | 12 Years - | Turning Point Therapeutics, Inc. | |
| Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations | NCT05845671 | Lung Cancer Non Small Cell ... | Amivantamab 105... Amivantamab 140... Amivantamab (to... Amivantamab (to... | 18 Years - 90 Years | University of Colorado, Denver | |
| Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE) | NCT02186821 | Tumors With Abe... | Ceritinib | 18 Years - | Novartis | |
| The Oncopanel Pilot (TOP) Study | NCT02171286 | Colorectal Canc... Advanced Non-Sm... Advanced Melano... Gastrointestina... Patients With D... | 18 Years - | British Columbia Cancer Agency | ||
| Study to Evaluate Clinical Real World Outcomes of Lorlatinib After Alectinib in ALK-Positive NSCLC Japanese Patients | NCT04979988 | ALK-positive No... | Lortlatinib | 20 Years - | Pfizer | |
| Lorlatinib Continuation Study | NCT05144997 | Non-Small-Cell ... NSCLC | Lorlatinib | 18 Years - | Pfizer | |
| ALK Rearrangements in Lung Adenocarcinoma: Epidemiology in Latin America (CLICaP) | NCT02502240 | Lung Cancer | 18 Years - 90 Years | Instituto Nacional de Cancerologia de Mexico | ||
| Lorlatinib Continuation Study | NCT05144997 | Non-Small-Cell ... NSCLC | Lorlatinib | 18 Years - | Pfizer | |
| Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity | NCT02314481 | Non-small Cell ... | MPDL3280A Vemurafenib Alectinib Trastuzumab emt... | 18 Years - | University College, London | |
| LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer | NCT01685138 | Non-Small Cell ... | LDK378 | 18 Years - | Novartis | |
| LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib. | NCT02450903 | Non-Small-Cell ... | LDK378 | 18 Years - | Novartis | |
| Crizotinib Continuation Clinical Study | NCT05160922 | NSCLC ALCL IMT | crizotinib | 1 Year - 99 Years | Pfizer | |
| Ceritinib Rare Indications Study in ALK+ Tumors | NCT02465528 | Tumors With Abe... Anaplastic Larg... Inflammatory My... Glioblastoma | Ceritinib (LDK3... | 18 Years - | Novartis | |
| A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors | NCT02422589 | ALK-positive Ad... | ceritinib warfarin midazolam | 18 Years - | Novartis | |
| Crizotinib (Xalkori) Expanded Access Protocol For The Treatment Of Adult Or Pediatric Patients | NCT02473497 | Neoplasm | Crizotinib | 0 Years - | Pfizer | |
| Pharmacogenomics IND EXEMPT SNP Clinical Study - Alectinib and Single Nucleotide Polymorphisms | NCT05987956 | Non-small Cell ... | Alectinib - Usu... Alectinib - Stu... | 22 Years - 75 Years | Medicine Invention Design, Inc | |
| An Investigational Drug, Crizotinib (PF-02341066), Is Being Studied In Tumors, Except Non-Small Cell Lung Cancer, That Are Positive For Anaplastic Lymphoma Kinase (ALK) | NCT01121588 | Neoplasms Malig... | Crizotinib | 15 Years - | Pfizer | |
| Neoadjuvant Therapy With Iruplinalkib for Potentially Resectable ALK Positive NSCLC: A Single Arm, Exploratory Trial | NCT06282536 | Potentially Res... | Iruplinalkib surgery | 18 Years - | Shanghai Pulmonary Hospital, Shanghai, China | |
| A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors | NCT02422589 | ALK-positive Ad... | ceritinib warfarin midazolam | 18 Years - | Novartis | |
| The Oncopanel Pilot (TOP) Study | NCT02171286 | Colorectal Canc... Advanced Non-Sm... Advanced Melano... Gastrointestina... Patients With D... | 18 Years - | British Columbia Cancer Agency | ||
| LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib | NCT02040870 | Non-Small Cell ... | LDK378 | 18 Years - | Novartis | |
| French National Observatory of the Patients With Non-small Cell Lung (NSCLC) and Molecular Testings | NCT01700582 | Carcinoma, Non-... ALK Gene Mutati... KRAS Gene Mutat... BRAF Gene Mutat... | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | ||
| A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors | NCT04644315 | Neoplasms Colorectal Neop... Melanoma Pancreatic Neop... Sarcoma Ovarian Neoplas... Brain Neoplasms Thyroid Neoplas... Neuroendocrine ... Cholangiocarcin... Salivary Gland ... Head and Neck N... Thyroid Cancer,... Lymphoma, Large... Neoplasms by Si... Respiratory Tra... Thoracic Neopla... Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Intestinal Neop... Gastrointestina... Digestive Syste... Digestive Syste... Gastrointestina... Colonic Disease... Intestinal Dise... Central Nervous... | Alectinib | 18 Years - | Hoffmann-La Roche | |
| A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma | NCT05456256 | Adenocarcinoma ... Carcinoma, Non-... | LP-300 Pemetrexed Carboplatin | 18 Years - | Lantern Pharma Inc. | |
| Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options | NCT02650401 | Solid Tumors CNS Tumors | Entrectinib | 0 Years - 18 Years | Hoffmann-La Roche | |
| LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib | NCT01828112 | Non-Small Cell ... | Ceritinib pemetrexed docetaxel | 18 Years - | Novartis | |
| A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements | NCT03093116 | Locally Advance... Metastatic Soli... | Oral repotrecti... | 12 Years - | Turning Point Therapeutics, Inc. | |
| Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer | NCT01625234 | Advanced Solid ... Non-small Cell ... | Phase I: X-396 ... Phase II: X-396... | 18 Years - | Xcovery Holdings, Inc. | |
| Ceritinib Rare Indications Study in ALK+ Tumors | NCT02465528 | Tumors With Abe... Anaplastic Larg... Inflammatory My... Glioblastoma | Ceritinib (LDK3... | 18 Years - | Novartis | |
| A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors | NCT04644315 | Neoplasms Colorectal Neop... Melanoma Pancreatic Neop... Sarcoma Ovarian Neoplas... Brain Neoplasms Thyroid Neoplas... Neuroendocrine ... Cholangiocarcin... Salivary Gland ... Head and Neck N... Thyroid Cancer,... Lymphoma, Large... Neoplasms by Si... Respiratory Tra... Thoracic Neopla... Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Intestinal Neop... Gastrointestina... Digestive Syste... Digestive Syste... Gastrointestina... Colonic Disease... Intestinal Dise... Central Nervous... | Alectinib | 18 Years - | Hoffmann-La Roche | |
| Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101) | NCT02584634 | Non-Small Cell ... | Avelumab PF-06463922 Crizotinib | 18 Years - | Pfizer | |
| LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer | NCT01828099 | Non-Small Cell ... | Ceritinib Pemetrexed Cisplatin Carboplatin | 18 Years - | Novartis | |
| Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer | NCT01625234 | Advanced Solid ... Non-small Cell ... | Phase I: X-396 ... Phase II: X-396... | 18 Years - | Xcovery Holdings, Inc. | |
| Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies | NCT05370469 | Lung Cancer EGFR Gene Mutat... EGFR ALK Gene Mutati... RET Gene Mutati... MET Gene Mutati... KRAS Mutation-R... BRAF ROS1 Gene Mutat... | Sensus Smartwat... RX Cap Fitbit Sense Surveys | 18 Years - | University of Virginia | |
| Crizotinib Continuation Clinical Study | NCT05160922 | NSCLC ALCL IMT | crizotinib | 1 Year - 99 Years | Pfizer | |
| Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50% | NCT04139317 | Non-small Cell ... | Capmatinib Pembrolizumab | 18 Years - | Novartis | |
| LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib | NCT02040870 | Non-Small Cell ... | LDK378 | 18 Years - | Novartis | |
| A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled | NCT06282991 | Non-Small Cell ... | Lorlatinib | 20 Years - | Pfizer | |
| LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer | NCT01685138 | Non-Small Cell ... | LDK378 | 18 Years - | Novartis | |
| LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer | NCT01685138 | Non-Small Cell ... | LDK378 | 18 Years - | Novartis | |
| Crizotinib Continuation Clinical Study | NCT05160922 | NSCLC ALCL IMT | crizotinib | 1 Year - 99 Years | Pfizer | |
| Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer | NCT02521051 | Non-Small Cell ... | Alectinib Bevacizumab | 18 Years - | Massachusetts General Hospital | |
| Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer | NCT05241028 | Non-small Cell ... | Ensartinib | 18 Years - 75 Years | Hebei Medical University Fourth Hospital | |
| A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer | NCT03131206 | ALK-positive No... RET-positive No... RET-positive Th... | Alectinib | 18 Years - | Dana-Farber Cancer Institute | |
| A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer | NCT03131206 | ALK-positive No... RET-positive No... RET-positive Th... | Alectinib | 18 Years - | Dana-Farber Cancer Institute | |
| Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50% | NCT04139317 | Non-small Cell ... | Capmatinib Pembrolizumab | 18 Years - | Novartis | |
| Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options | NCT02650401 | Solid Tumors CNS Tumors | Entrectinib | 0 Years - 18 Years | Hoffmann-La Roche | |
| Neoadjuvant Therapy With Iruplinalkib for Potentially Resectable ALK Positive NSCLC: A Single Arm, Exploratory Trial | NCT06282536 | Potentially Res... | Iruplinalkib surgery | 18 Years - | Shanghai Pulmonary Hospital, Shanghai, China |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
